Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Sharp & Dohme has said that Isentress has been granted approval from the European Union Commission for use in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Subscribe to our email newsletter
The commission’s decision is applicable to the 27 member states of the European Union (EU), including France, Germany, Italy, Spain and the UK. Separate national licenses, based on the commission’s decision, will also be issued in European Economic Area Member States Iceland and Norway.
Ken Frazier, executive vice president and president, global human health, Merck & Co., said: “This approval marks another milestone in Merck Sharp & Dohme’s continued commitment to combating HIV and AIDS by conducting research for breakthrough medicines, developing business models that help our products reach as many people as possible, and participating in partnerships to help build infrastructure and address health and development challenges around the world.”